SBIR/STTR Research Award
Malarial Vaccines Utilizing Antigen/Adjuvant Display on Viral-Like Particles
Award amount
$120,000Program and phase
SBIR · Phase IAward year
2009Award details
- Awarding agency
- Department of Defense
- Branch
- Army
- Recipient company
- AGAVE BIOSYSTEMS INC.
- Proposal award date
- 2009-11-01
- Contract end date
- 2010-05-31
- UEI
- SDSPMQR27BH4
- Solicitation number
- 2009.2
- Topic code
- A09-107
Research abstract
Development of an effective malarial vaccine has been slow, although recent success in vaccine development has been achieved by using the Plasmodium falciparum circumsporozoite surface protein (CSP)-hepatitis B surface antigen fusions, in conjunction with hepatitis B particles (the RTS, S formulation). The results of these studies suggest the potential of improved malarial vaccines by use of the viral-like particle (VLP)-linked immunogen approach. The VLP technology is being utilized for the development of vaccines for a variety of diseases. Agave BioSystems proposes to develop a novel platform for development of malarial vaccines consisting of a VLP displayed malarial antigen/adjuvant based on the Norwalk virus (NV) capsid protein. The NV-VLP will be engineered to express a candidate antigen in combination with a peptide adjuvant. These VLPs will be characterized, purified and delivered for testing of efficacy to stimulate cellular and humoral immune responses.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Novel Screen Approach to Inactivate Whole Viral Vaccines by Supralethal Irradiation
- Identification of Patients with Clostridium Difficile Infection, Colonization and/or Reoccurrence
- Intracellular Detection of Small Molecules in Live Cells
- Multiplex Immunoassays in the Development of Vaccines Against Enteric Pathogens
- Screens for Novel Agonists/Antagonists of Endocrine Fibroblast Growth Factors
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Malarial Vaccines Utilizing Antigen/Adjuvant Display on Viral-Like Particles
- GeMI-Vax as a multi-life stage malaria vaccine
- GeMI-Vax as a multi-life stage malaria vaccine
Research funding history
102 SBIR/STTR records share this UEI (1998–2015). Reported award amounts total $29,837,745. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Defense, Department of Health and Human Services, National Aeronautics and Space Administration, Environmental Protection Agency